by Clinical Neuropsychologist | Saturday, March 29, 2025 | Dementia
Abstract INTRODUCTION Cerebral amyloid angiopathy (CAA) is characterized by the deposition of beta-amyloid (Aβ) in small vessels leading to hemorrhagic stroke and dementia. This study examined whether plasma Aβ42/40, phosphorylated-tau (p-tau), neurofilament light...
by Clinical Neuropsychologist | Saturday, March 29, 2025 | Dementia
Abstract INTRODUCTION Mixed evidence on how statin use affects risk of Alzheimer’s disease and related dementias (ADRD) may reflect heterogeneity across sociodemographic factors. Few studies have sufficient power to evaluate effect modifiers. METHODS Kaiser...
by Clinical Neuropsychologist | Saturday, March 29, 2025 | Dementia
Abstract INTRODUCTION Comorbid conditions associated with Alzheimer’s disease (AD) are poorly understood regarding timing and potential impact on disease onset and progression. METHODS Medical Information Mart for Intensive Care-IV electronic health records from...
by Clinical Neuropsychologist | Wednesday, March 26, 2025 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) selectively affects certain brain regions, yet the mechanisms of selective vulnerability remain poorly understood. The neuromodulatory subcortical system, which includes nuclei exhibiting a range of vulnerability...
by Clinical Neuropsychologist | Wednesday, March 26, 2025 | Dementia
Abstract INTRODUCTION Plasma phosphorylated threonine 181 of tau (pTau181) and amyloid beta (Aβ) are biomarkers for differential diagnosis and preclinical detection of Alzheimer disease (AD). Given differences in AD risk across diverse populations,...
by Clinical Neuropsychologist | Wednesday, March 26, 2025 | Dementia
Abstract INTRODUCTION Distinguishing between molecular changes that precede dementia onset and those resulting from the disease is challenging with cross-sectional studies. METHODS We studied blood DNA methylation (DNAm) differences and incident dementia in two large...
